Search clinical trials for: Laryngopharyngeal reflux (LPR)

Total 1453 results

Foregut Research Foundation

Not yet recruiting

Ovitex in Paraesophageal and Large Hiatal Hernia Repair (OviPHeR)

Paraesophageal Hernia | Large Hiatal Hernia

United States
Brigham and Women's Hospital
EndoGastric Solutions

Not yet recruiting

Transoral Incisionless Fundoplication (TIF) for Laryngopharyngeal Reflux (LPR) Patients (TIF-LPR)

Gastroesophageal Reflux Disease (GERD) | Motility Disorder | Laryngopharyngeal Reflux (LPR) | Reflux Disease, Gastro-Esophageal

United States
University of Washington
Takeda Pharmaceuticals North America, Inc.

Withdrawn

Evaluating Treatment Response in Laryngo-Pharyngeal Reflux

Laryngo-pharyngeal Reflux

United States
Advanced Center for Specialty Care
Takeda

Unknown

Dexlansoprazole to Treat Laryngopharyngeal Reflux and Lingual Tonsil Hypertrophy

Laryngopharyngeal Reflux | Hypertrophy of Lingual Tonsil

United States
The Functional Gut Clinic
Rosa Biotech

Recruiting

LPR Fluorescence Pilot

Gastro Esophageal Reflux | Laryngopharyngeal Reflux

United Kingdom
CDx Diagnostics
Rambam Health Care Campus

Withdrawn

CDx Biopsies for Detection of Laryngopharyngeal Reflux and Laryngeal Lesions

Laryngopharyngeal Reflux | Laryngeal Disease | Laryngeal Tumor
Medical College of Wisconsin

Not yet recruiting

Lexiva for the Treatment of LPR

Laryngopharyngeal Reflux

United States
Assiut University

Unknown

Effect of CPAP Therapy on LPR Among Patients With OSAS

Obstructive Sleep Apnea | Laryngopharyngeal Reflux
Kazakh Medical University of Continuing Education

Completed

Method of Early Diagnosis of Laryngopharyngeal Reflux (LPR)

Gastro Esophageal Reflux | Laryngopharyngeal Reflux | Laryngitis | Laryngopharyngitis Chronic

Kazakhstan
Hodge, Kenneth M., M.D.
TAP Pharmaceutical Products Inc.

Unknown

Prevacid vs Lifestyle Modifications for the Treatment of LPR

Laryngopharyngeal Reflux

United States
Chulalongkorn University
Sanpasitthiprasong Hospital; Burapha University

Completed

Lime Powder Regimen (LPR) for Prevention of Renal Stone Recurrence

Urolithiasis

Thailand
AstraZeneca

Completed

Quality of Life Validation in Laryngitis

Laryngopharyngeal Reflux (LPR)
Temple University

Withdrawn

Comparison of Voice Therapy and Antireflex Therapy in LPR

Laryngopharyngeal Reflux

United States
Emory University
AstraZeneca; Respiratory Technology Corporation

Completed

Study of an Oropharyngeal Aerosolized pH Probe for Diagnosing Laryngopharyngeal Reflux (LPR)

Laryngopharyngeal Reflux

United States
Children's Hospital of Philadelphia

Withdrawn

A New Nasopharyngeal pH Probe for Diagnosis of Laryngopharyngeal Reflux

Laryngopharyngeal Reflux

United States
University of Manitoba
Wakunga of America Co. Ltd.; Purity Life Health Products LP

Completed

Double-Blind, Randomized, Cross-Over Trial of Aged Garlic Extract for Hypertension

Hypertension

Canada
Northwestern University
Respiratory Technology Corporation

Completed

Positive Predictive Value of the Dx-pH Probe for Predicting PPI Response in LPR

Extraesophageal Reflux | Laryngopharyngeal Reflux (LPR) | Reflux Laryngitis | Posterior Laryngitis

United States
University Hospitals of North Midlands NHS Trust

Recruiting

What is the Experience of the Professional Nurse Advocates (PNAs) Application of the A-EQUIP Model Into Practice

Professional Role | Staff Attitude

United Kingdom
National Cancer Institute (NCI)

Terminated

Bortezomib in Treating Patients With Advanced Non-small Cell Lung Cancer

Stage IIIB Non-small Cell Lung Cancer | Recurrent Non-small Cell Lung Cancer | Stage IV Non-small Cell Lung Cancer

United States
National Cancer Institute (NCI)

Completed

Bortezomib in Treating Patients With Lymphoproliferative Disorders

Recurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma | Recurrent Grade 3 Follicular Lymphoma | Recurrent Mantle Cell Lymphoma

United States
National Cancer Institute (NCI)

Terminated

Bortezomib in Treating Patients With Recurrent Glioma

Adult Anaplastic Astrocytoma | Adult Anaplastic Oligodendroglioma | Adult Giant Cell Glioblastoma | Adult Glioblastoma | Adult Gliosarcoma | Recurrent Adult Brain Tumor

United States
National Cancer Institute (NCI)

Completed

PS-341 in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myeloid Leukemia in Blast Phase, or Myelodysplastic Syndrome

Recurrent Adult Acute Myeloid Leukemia | Adult Acute Promyelocytic Leukemia (M3) | Previously Treated Myelodysplastic Syndromes | Recurrent Adult Acute Lymphoblastic Leukemia | Relapsing Chronic Myelogenous Leukemia | Refractory Anemia With Excess Blasts | Blastic Phase Chronic Myelogenous Leukemia and other conditions

United States
National Cancer Institute (NCI)

Completed

Bortezomib in Treating Patients With Metastatic Thyroid Cancer That Did Not Respond to Radioactive Iodine Therapy

Insular Thyroid Cancer | Recurrent Thyroid Cancer | Stage II Follicular Thyroid Cancer | Stage II Papillary Thyroid Cancer | Stage IV Follicular Thyroid Cancer | Stage IV Papillary Thyroid Cancer

United States
The Heartburn Foundation

Active, not recruiting

Registry of Outcomes From AntiReflux Surgery (ROARS)

Hiatal Hernia | Gastroesophageal Reflux Disease

United States
National Cancer Institute (NCI)

Completed

PS-341 in Treating Women With Metastatic Breast Cancer

Stage IV Breast Cancer | Recurrent Breast Cancer

United States
National Cancer Institute (NCI)

Completed

PS-341 in Treating Patients With Metastatic Malignant Melanoma

Recurrent Melanoma | Stage IV Melanoma

United States
Loma Linda University

Withdrawn

The Study of Eustachian Tube Dysfunction and Laryngopharyngeal Reflux (ETDLPR)

Laryngopharyngeal Reflux | Eustachian Tube Dysfunction

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Terminated

Bortezomib in Treating Patients With High-Risk Acute Myeloid Leukemia in Remission

Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome | Adult Acute Minimally Differentiated Myeloid Leukemia (M0) | Adult Acute Myeloblastic Leukemia Without Maturation (M1) | Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities | Adult Acute Myeloid... and other conditions

United States
National Cancer Institute (NCI)

Completed

Phase II Trial Of PS-341 (Bortezomib) In Patients With Previously Treated Advanced Urothelial Tract Transitional Cell Carcinoma

Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter | Recurrent Bladder Cancer | Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter | Stage III Bladder Cancer | Stage IV Bladder Cancer | Transitional Cell Carcinoma of the Bladder | Ureter Cancer | Recurrent Urethral... and other conditions

United States
National Cancer Institute (NCI)

Completed

Bortezomib in Treating Patients With Advanced Cancer and Liver Dysfunction

Malignant Neoplasm | Hepatic Complications

United States
National Cancer Institute (NCI)

Terminated

Tanespimycin and Bortezomib in Treating Patients With Advanced Solid Tumors or Lymphomas

Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell Lymphoma | Recurrent Adult Burkitt Lymphoma | Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Adult Diffuse Mixed Cell Lymphoma | Recurrent Adult Diffuse Small Cleaved Cell Lymphoma and other conditions

United States
National Cancer Institute (NCI)

Completed

Bortezomib in Treating Patients With Newly Diagnosed Multiple Myeloma

Stage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma

United States
National Cancer Institute (NCI)

Terminated

17-N-Allylamino-17-Demethoxygeldanamycin and Bortezomib in Treating Patients With Relapsed or Refractory Hematologic Cancer

Recurrent Adult Acute Myeloid Leukemia | Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell Lymphoma | Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma | Recurrent... and other conditions

United States
OHSU Knight Cancer Institute
National Cancer Institute (NCI); GlaxoSmithKline; Millennium Pharmaceuticals,...

Terminated

Ofatumumab and Bortezomib in Subjects With Relapsed CD20+Diffuse Large B Cell, Follicular, or Mantle Cell Lymphoma

Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma | Recurrent Grade 3 Follicular Lymphoma | Recurrent Mantle Cell Lymphoma

United States
National Cancer Institute (NCI)

Completed

Bortezomib in Treating Patients With Hepatocellular Carcinoma (Liver Cancer)

Advanced Adult Primary Liver Cancer | Localized Unresectable Adult Primary Liver Cancer | Recurrent Adult Primary Liver Cancer | Adult Primary Hepatocellular Carcinoma

United States
National Cancer Institute (NCI)

Completed

Bortezomib in Treating Children With Advanced Solid Tumors

Unspecified Childhood Solid Tumor, Protocol Specific

United States
National Cancer Institute (NCI)

Completed

Bortezomib in Treating Patients With Advanced Cancer and Kidney Dysfunction

Stage III Multiple Myeloma | Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell Lymphoma | Recurrent Adult Burkitt Lymphoma | Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Adult Diffuse Mixed Cell Lymphoma | Recurrent Adult Diffuse... and other conditions

United States
Roswell Park Cancer Institute
National Cancer Institute (NCI); GlaxoSmithKline

Terminated

Ofatumumab and Bortezomib in Treating Patients With Previously Untreated Waldenstrom Macroglobulinemia

Waldenström Macroglobulinemia

United States
National Cancer Institute (NCI)

Completed

Bortezomib in Treating Young Patients With Refractory or Recurrent Leukemia

Childhood Acute Promyelocytic Leukemia (M3) | Recurrent Childhood Acute Lymphoblastic Leukemia | Recurrent Childhood Acute Myeloid Leukemia | Blastic Phase Chronic Myelogenous Leukemia

United States
Barbara Ann Karmanos Cancer Institute
National Cancer Institute (NCI)

Completed

Bortezomib and Filgrastim to Promote Stem Cell Mobilization in Patients With Non-Hodgkin Lymphoma or Multiple Myeloma

Stage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell Lymphoma | Recurrent Adult Burkitt Lymphoma | Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Adult... and other conditions

United States
Mayo Clinic

Completed

Aurora A Kinase Inhibitor MLN8237 and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma

Refractory Multiple Myeloma

United States
National Cancer Institute (NCI)
Gynecologic Oncology Group

Completed

Bortezomib in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer or Primary Peritoneal Cancer

Primary Peritoneal Cavity Cancer | Recurrent Ovarian Epithelial Cancer

United States
National Cancer Institute (NCI)

Terminated

Obatoclax and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma

Stage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple Myeloma

United States
National Cancer Institute (NCI)

Completed

PXD101 and Bortezomib in Treating Patients With Advanced Solid Tumors or Lymphomas

Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell Lymphoma | Recurrent Adult Burkitt Lymphoma | Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Adult Diffuse Mixed Cell Lymphoma | Recurrent Adult Diffuse Small Cleaved Cell Lymphoma and other conditions

United States
National Cancer Institute (NCI)

Terminated

Oxaliplatin and Bortezomib in Treating Patients With Advanced Cancer

Unspecified Adult Solid Tumor, Protocol Specific

United States
National Cancer Institute (NCI)

Completed

Bortezomib With or Without Irinotecan in Treating Patients With Cancer of the Gastroesophageal Junction or Stomach

Adenocarcinoma of the Gastroesophageal Junction | Stage IV Gastric Cancer | Recurrent Gastric Cancer | Diffuse Adenocarcinoma of the Stomach | Intestinal Adenocarcinoma of the Stomach | Mixed Adenocarcinoma of the Stomach | Stage IIIB Gastric Cancer | Stage IIIC Gastric Cancer

United States
National Cancer Institute (NCI)

Terminated

Obatoclax and Bortezomib in Treating Patients With Aggressive Relapsed or Recurrent Non-Hodgkin Lymphoma

Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma | Recurrent Grade 3 Follicular Lymphoma | Recurrent Mantle Cell Lymphoma | Recurrent Marginal Zone Lymphoma | Recurrent Small Lymphocytic Lymphoma | Adult Non-Hodgkin Lymphoma

United States
National Cancer Institute (NCI)

Completed

Vorinostat and Bortezomib in Treating Patients With Metastatic or Unresectable Solid Tumors

Unspecified Adult Solid Tumor, Protocol Specific

United States
National Cancer Institute (NCI)

Completed

Vorinostat and Bortezomib in Treating Patients With Advanced Soft Tissue Sarcoma

Recurrent Adult Soft Tissue Sarcoma | Stage III Adult Soft Tissue Sarcoma | Stage IV Adult Soft Tissue Sarcoma

United States
National Cancer Institute (NCI)

Completed

Vorinostat and Bortezomib in Treating Patients With Progressive, Recurrent Glioblastoma Multiforme

Adult Giant Cell Glioblastoma | Adult Glioblastoma | Adult Gliosarcoma | Recurrent Adult Brain Tumor

United States

Search clinical trials for: Laryngopharyngeal reflux (LPR)

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Switzerland

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations